Analysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $11.36

Vor Biopharma Inc. (NYSE:VOR) has earned an average rating of “Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last year is $11.36.

Several equities analysts have recently commented on VOR shares. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Vor Biopharma in a report on Friday, November 8th. Barclays reduced their price objective on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a research report on Friday, September 6th. HC Wainwright reiterated a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a research note on Friday, November 8th. Finally, Robert W. Baird lowered their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, November 8th.

Vor Biopharma Price Performance

VOR stock opened at $0.79 on Friday. The firm has a market cap of $54.25 million, a price-to-earnings ratio of -0.48 and a beta of -0.40. Vor Biopharma has a 1-year low of $0.63 and a 1-year high of $3.14. The firm has a fifty day moving average price of $0.78 and a two-hundred day moving average price of $1.00.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) EPS for the quarter, meeting the consensus estimate of ($0.40). As a group, analysts expect that Vor Biopharma will post -1.55 EPS for the current fiscal year.

Institutional Trading of Vor Biopharma

Several hedge funds have recently added to or reduced their stakes in VOR. Vanguard Group Inc. increased its holdings in shares of Vor Biopharma by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after purchasing an additional 69,436 shares during the period. Acadian Asset Management LLC bought a new position in Vor Biopharma in the 1st quarter valued at about $126,000. Renaissance Technologies LLC increased its stake in Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after buying an additional 160,642 shares during the period. Hsbc Holdings PLC raised its position in shares of Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after buying an additional 31,333 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Vor Biopharma in the second quarter worth approximately $53,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.